Blodgett Wealth Advisors LLC Cuts Holdings in Eli Lilly and Company (NYSE:LLY)

Blodgett Wealth Advisors LLC lowered its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,449 shares of the company’s stock after selling 30 shares during the period. Eli Lilly and Company accounts for approximately 2.1% of Blodgett Wealth Advisors LLC’s holdings, making the stock its 8th biggest holding. Blodgett Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $2,010,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares in the last quarter. Northern Trust Corp increased its holdings in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Eli Lilly and Company by 2.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after buying an additional 88,016 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Up 1.2 %

Shares of Eli Lilly and Company stock traded up $8.64 during trading on Friday, hitting $733.51. 2,009,249 shares of the stock traded hands, compared to its average volume of 2,265,427. The firm has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78. The stock’s fifty day simple moving average is $761.79 and its 200 day simple moving average is $666.06.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.09 earnings per share. On average, equities analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.